European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure71
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study61
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee61
Early initiation of SGLT2 inhibitors after acute myocardial infarction51
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?46
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials38
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials38
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study37
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients35
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor33
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis32
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy31
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient30
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis29
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study29
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective29
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study29
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia27
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives27
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease26
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials25
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis25
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’22
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy22
New ways of mitigating aldosterone in cardiorenal disease21
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy21
All about clinical trials21
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data21
Late breaking clinical trials at ACC 2220
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization20
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis20
Long-term antiplatelet monotherapy after PCI: searching for the smart choice20
De-escalation versus shortening of dual antiplatelet therapy19
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients19
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease18
Cardiovascular prevention and risk factors18
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-18
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al.18
News in cardiovascular pharmacotherapy from the ACC.24 Meeting17
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!16
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic16
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial16
Photoinduced skin reactions of cardiovascular drugs—a systematic review15
Entering a new era of antiplatelet therapy: the 4D-ACS trial15
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts15
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results15
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis15
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials15
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry15
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation14
Are NOACs always the best strategy in elderly AF patients?14
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry14
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial14
Focus on different aspects of atrial fibrillation14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202314
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes13
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation13
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202213
What's new in pharmacotherapy at ESC Congress 2023?13
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis13
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?13
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study13
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis13
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue12
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis12
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?12
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry12
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr11
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial11
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF11
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy11
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials11
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study11
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials11
FLOW trial stopped early due to evidence of renal protection with semaglutide10
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm10
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study10
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study10
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark10
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists10
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease10
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure9
RNA-targeted therapeutics in cardiovascular disease: the time is now9
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding9
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation9
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study9
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis9
Special focus on the new anti-diabetic drugs8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis8
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies8
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study8
Future of antithrombotic therapy for heart failure with coronary artery disease8
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study8
News in cardiovascular pharmacotherapy from the ACC.25 Meeting8
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial8
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?8
0.14530301094055